Filing Details

Accession Number:
0002007919-24-000045
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-09-10 17:00:58
Reporting Period:
2024-09-06
Accepted Time:
2024-09-10 17:00:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
2007919 Inhibrx Biosciences Inc. INBX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1366074 Mark Lappe C/O Inhibrx Biosciences, Inc.
11025 North Torrey Pines Road, Suite 140
La Jolla CA 92037
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-09-06 26,000 $15.29 647,548 No 4 P Indirect By the Lappe Family Trust
Common Stock Acquisiton 2024-09-09 9,500 $15.21 657,048 No 4 P Indirect By the Lappe Family Trust
Common Stock Acquisiton 2024-09-10 8,500 $15.19 665,548 No 4 P Indirect By the Lappe Family Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By the Lappe Family Trust
No 4 P Indirect By the Lappe Family Trust
No 4 P Indirect By the Lappe Family Trust
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 165,000 Indirect By Lappe Descendants' Trust
Common Stock 54,865 Indirect The Mark Paul Lappe Roth IRA
Footnotes
  1. The shares were purchased in multiple transactions at prices ranging from $15.04 to $15.70, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  2. These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.
  3. The shares were purchased in multiple transactions at prices ranging from $15.08 to $15.50, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  4. The shares were purchased in multiple transactions at prices ranging from $15.01 to $15.26, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  5. These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.